E. Ohman J or Asset Management AB Invests $614,000 in Teva Pharmaceutical Industries Ltd. $TEVA

E. Ohman J or Asset Management AB acquired a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 19,680 shares of the company’s stock, valued at approximately $614,000.

A number of other hedge funds have also modified their holdings of TEVA. Grove Bank & Trust boosted its position in Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after purchasing an additional 750 shares during the last quarter. Advisors Asset Management Inc. acquired a new stake in Teva Pharmaceutical Industries in the second quarter valued at approximately $41,000. Cromwell Holdings LLC grew its position in Teva Pharmaceutical Industries by 40.3% in the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after acquiring an additional 629 shares in the last quarter. MAI Capital Management increased its stake in shares of Teva Pharmaceutical Industries by 26.8% during the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after purchasing an additional 697 shares during the last quarter. Finally, Rothschild Investment LLC increased its stake in shares of Teva Pharmaceutical Industries by 97.0% during the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock worth $55,000 after purchasing an additional 1,348 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 14,150 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $448,130.50. Following the sale, the insider owned 6,774 shares in the company, valued at $214,532.58. The trade was a 67.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Richard D. Francis sold 442,935 shares of the business’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $32.36, for a total transaction of $14,333,376.60. Following the completion of the sale, the chief executive officer directly owned 642,099 shares in the company, valued at $20,778,323.64. This trade represents a 40.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 920,901 shares of company stock valued at $30,056,789 over the last 90 days. Corporate insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 1.0%

TEVA stock opened at $29.44 on Thursday. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $37.35. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The company has a market cap of $33.85 billion, a PE ratio of 24.53, a price-to-earnings-growth ratio of 9.75 and a beta of 0.72. The business’s 50-day simple moving average is $32.45 and its 200 day simple moving average is $27.28.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the company earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Truist Financial lifted their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. The Goldman Sachs Group increased their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Jefferies Financial Group raised their target price on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Finally, Scotiabank upped their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research note on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average target price of $37.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.